PODD · Insulet Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.71B | $2.07B | $1.70B | $1.06B | $1.10B | $904.40M |
| Cost of Revenue | $768.20M | $625.90M | $537.20M | $499.70M | $346.70M | $322.10M |
| Gross Profit | $1.94B | $1.45B | $1.16B | $805.60M | $752.10M | $582.30M |
| R&D | $301.10M | $219.60M | $205.00M | $180.20M | $160.10M | $146.80M |
| SG&A | $1.17B | $917.20M | $734.90M | $587.80M | $466.00M | $384.00M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $90.40M | $80.80M | $72.80M | $63.20M | $57.40M | $55.40M |
| Operating Income | $473.80M | $308.90M | $220.00M | $37.60M | $126.00M | $51.50M |
| Interest Expense | $59.40M | $42.70M | $36.20M | $36.50M | $61.70M | $48.10M |
| Income Tax | $92.40M | ($118.10M) | $8.30M | $5.20M | $3.70M | $2.90M |
| Net Income | $247.10M | $418.30M | $206.30M | $4.60M | $16.80M | $6.80M |
| EPS - Basic | $3.51 | $5.97 | $2.96 | $0.07 | $0.25 | $0.11 |
| EPS - Diluted | $3.48 | $5.78 | $2.94 | $0.07 | $0.24 | $0.10 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $716.10M | $953.40M | $704.20M | $689.70M | $806.40M | $907.20M |
| Accounts Receivable | - | - | - | $140.90M | $161.00M | $83.80M |
| Inventory | $452.60M | $430.40M | $402.60M | $346.80M | $303.20M | $154.30M |
| Accounts Payable | $75.00M | $19.80M | $19.20M | $30.80M | $37.70M | $54.10M |
| Current Assets | $1.91B | $1.89B | $1.58B | $1.31B | $1.33B | $1.25B |
| Total Assets | $3.19B | $3.09B | $2.59B | $2.25B | $2.05B | $1.87B |
| Current Liabilities | $680.10M | $528.40M | $451.20M | $364.70M | $228.80M | $207.80M |
| Long-term Debt | - | - | - | $1.37B | $1.25B | $1.04B |
| Total Liabilities | $1.68B | $1.88B | $1.86B | $1.77B | $1.49B | $1.27B |
| Stockholders' Equity | $1.52B | $1.21B | $732.70M | $476.40M | $556.30M | $603.60M |
| Retained Earnings | $287.40M | $40.30M | ($378.00M) | ($584.30M) | ($649.50M) | ($666.30M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $569.30M | $430.30M | $145.70M | $119.00M | ($68.10M) | $84.00M |
| Investing Cash Flow | ($222.70M) | ($146.20M) | ($119.40M) | ($191.10M) | ($82.70M) | $14.00M |
| Financing Cash Flow | ($595.30M) | ($28.10M) | ($13.60M) | ($40.30M) | $40.70M | $605.50M |
| CapEx | $191.60M | $124.90M | $75.60M | $122.90M | $111.90M | $129.00M |
| Free Cash Flow | $377.70M | $305.40M | $70.10M | ($3.90M) | ($180.00M) | ($45.00M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 71.6% | 69.8% | 68.3% | 76.3% | 68.4% | 64.4% |
| Operating margin | 17.5% | 14.9% | 13.0% | 3.6% | 11.5% | 5.7% |
| EBITDA margin | 20.8% | 18.8% | 17.3% | 9.6% | 16.7% | 11.8% |
| Net margin | 9.1% | 20.2% | 12.2% | 0.4% | 1.5% | 0.8% |
| Free cash flow margin | 13.9% | 14.7% | 4.1% | -0.4% | -16.4% | -5.0% |
| FCF / Net income | 1.53 | 0.73 | 0.34 | -0.85 | -10.71 | -6.62 |
| R&D / Revenue | 11.1% | 10.6% | 12.1% | 17.1% | 14.6% | 16.2% |
| SG&A / Revenue | 43.0% | 44.3% | 43.3% | 55.7% | 42.4% | 42.5% |
| Effective tax rate | 27.2% | -39.3% | 3.9% | 53.1% | 18.0% | 29.9% |
| Return on assets | 7.7% | 13.5% | 8.0% | 0.2% | 0.8% | 0.4% |
| Return on equity | 16.3% | 34.5% | 28.2% | 1.0% | 3.0% | 1.1% |
| Return on invested capital | - | - | - | 1.0% | 5.7% | 2.2% |
| Liquidity | ||||||
| Current ratio | 2.81 | 3.58 | 3.51 | 3.60 | 5.81 | 6.01 |
| Quick ratio | 2.15 | 2.76 | 2.62 | 2.65 | 4.49 | 5.27 |
| Cash ratio | 1.05 | 1.80 | 1.56 | 1.89 | 3.52 | 4.37 |
| Leverage | ||||||
| Debt / Equity | - | - | - | 2.88 | 2.24 | 1.73 |
| Debt / Assets | - | - | - | 0.61 | 0.61 | 0.56 |
| Debt / EBITDA | - | - | - | 13.63 | 6.81 | 9.76 |
| Interest coverage | 8.0x | 7.2x | 6.1x | 1.0x | 2.0x | 1.1x |
| Equity multiplier | 2.11 | 2.55 | 3.53 | 4.73 | 3.68 | 3.10 |
| Liabilities / Assets | 0.53 | 0.61 | 0.72 | 0.79 | 0.73 | 0.68 |
| Efficiency | ||||||
| Asset turnover | 0.85 | 0.67 | 0.66 | 0.47 | 0.54 | 0.48 |
| Inventory turnover | 1.70 | 1.45 | 1.33 | 1.44 | 1.14 | 2.09 |
| Days sales outstanding | - | - | - | 49d | 53d | 34d |
| Days inventory outstanding | 215d | 251d | 274d | 253d | 319d | 175d |
| Days payable outstanding | 36d | 12d | 13d | 22d | 40d | 61d |
| Cash conversion cycle | - | - | - | 280d | 333d | 147d |
| Valuation | ||||||
| P / E | 81.7x | 45.2x | 73.8x | 4205.6x | 1108.6x | 2556.3x |
| P / B | 13.5x | 15.9x | 21.8x | 43.2x | 32.8x | 27.9x |
| P / S | 7.5x | 9.3x | 9.4x | 19.5x | 16.6x | 18.6x |
| EV / EBITDA | 34.9x | 47.1x | 52.2x | 211.0x | 101.9x | 159.0x |
| Growth | ||||||
| Revenue growth (YoY) | 30.7% | 22.1% | 60.8% | -3.9% | 21.5% | 22.5% |
| Revenue CAGR (3y) | 36.9% | 23.5% | 23.3% | 12.7% | 44.1% | 24.9% |
| Revenue CAGR (5y) | 24.5% | 22.9% | 35.8% | 17.9% | 24.5% | 22.8% |
| Gross profit growth (YoY) | 34.2% | 24.6% | 44.0% | 7.1% | 29.2% | 21.2% |
| Operating income growth (YoY) | 53.4% | 40.4% | 485.1% | -70.2% | 144.7% | 3.0% |
| Net income growth (YoY) | -40.9% | 102.8% | 4384.8% | -72.6% | 147.1% | -41.4% |
| EPS growth (YoY) | -39.8% | 96.6% | 4100.0% | -70.8% | 140.0% | -47.4% |
| EPS CAGR (3y) | 267.7% | 188.8% | 208.6% | -28.3% | - | - |
| EPS CAGR (5y) | 103.4% | 98.0% | - | - | - | - |
| FCF growth (YoY) | 23.7% | 335.7% | - | 97.8% | -300.0% | 31.1% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 25.1% | 65.4% | 53.8% | -14.4% | -7.8% | 695.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$5.38B totalProduct Omnipod$2.67B · 49.7%
U.S.Omnipod$1.92B · 35.7%
International Omnipod$754.30M · 14.0%
Drug Delivery$34.10M · 0.6%
Geographic
$2.71B totalUS$1.95B · 72.1%
Non Us$754.30M · 27.9%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
2.04
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing INSULET CORP against the 5 most active filers in the same SIC group.